Institute of Poisons and Drugs, Academy of Military Medical Sciences, PLA

Primary objective: To evaluate the effects of high-fat and low-fat meals on the pharmacokinetic characteristics of a single oral dose of enteric-coated amuletine hydrochloride tablets in healthy subjects Secondary objective: To evaluate the safety and tolerability of a single oral dose of enteric-coated amuletine hydrochloride tablets in healthy subjects after a high-fat and low-fat meal

1. Evaluate the safety and tolerability of single-dose oral Baxuan tablets in healthy Chinese adult subjects; 2. Evaluate the safety and tolerability of multiple-dose oral Baxuan tablets in healthy Chinese adult subjects; 3. Explore the pharmacokinetic characteristics of oral Baxuan tablets in healthy Chinese adult subjects.

This study aimed to investigate the pharmacokinetic characteristics of a single fasting and postprandial oral administration of oseltamivir phosphate orodisintegrating tablets (Xinghao Meiying®, 30 mg) developed by Beijing Xinghao Pharmaceutical Co., Ltd. and produced by Beijing Xinghao Yingsheng Pharmaceutical Co., Ltd.; using oseltamivir phosphate dry suspension (Tamiflu®, 6 mg/mL) produced by Roche Pharma AG as the reference preparation, to compare the pharmacokinetic parameters of the two preparations, including Cmax, AUC0-t, and AUC0-∞, to evaluate the bioequivalence of the two preparations in humans, and to evaluate the effect of a high-fat and high-calorie meal on the bioavailability of the test preparation.